Autologous bone marrow transplantation in hematological malignancies

摘要: Autologous bone marrow transplantation (ABMT) has developed considerably in the past 15 years and is now a routine procedure for consolidation of acute leukemias, non-Hodgkin's lymphomas Hodgkin's disease. In addition, ABMT been tested multiple myeloma (MM) even considered highly selected cases chronic myelocytic leukemia (CML). Interest resulted from discovery new purging procedures such as long-term cultures with or without serum-free media containing various lymphokines, evaluation cryoinjury on malignant cells, increased detection minimal residual disease using PCR, acceleration hemopoietic recovery post-ABMT through use peripheral blood stem cells and/or lymphokines. Results presented include data international (ABMTR) European (EBMT) registries, our own unit Paris. With respect to (a) EBMT listed 1,688 patients. The overall results were follows: patients autografted complete remission (CR) 1, leukemia-free survival relapse rate at 7 48 +/- 2% 41 3% AML 44 5% 45 lymphoblastic (ALL), respectively. CR2, figures 34 4% 54 32 62 ALL, Patients not relapsing 1 year had probability being cured 86 71% if CR1 CR2 81 59% Multivariate analysis rates several subpopulations confirmed efficacy CR1: transplanted prior January 1988 (minimum follow-up 2 years), purged was 35 vs. 47 (p less than 0.005). (b) Paris, St-Antoine, TBI mafosfamide levels individually adjusted (Blood 1986;67:1367), DFS 84 62% 63 ALL CR1, There statistically significant relationship between amount CFUGM progenitors after purging. cutoff point 0.3%, 54% those receiving higher fractions only 29% less. lymphomas, 698 intermediate high grade 6 30% 18% sensitive resistant relapses, respectively.(ABSTRACT TRUNCATED AT 400 WORDS)